Im Gun-Il
Department of Orthopaedics, Dongguk University Ilsan Hospital, Dongguk-Ro 27, Goyang, Republic of Korea.
Tissue Eng Regen Med. 2025 Jun 6. doi: 10.1007/s13770-025-00722-z.
Recently, regenerative medicine based on cell-based therapies has emerged as a therapeutic possibility for the management of osteoarthritis (OA). Stromal vascular fraction (SVF) is a cellular mixture obtained from lipoaspirate processed through either mechanical or enzymatic separation. SVF has been applied in several countries to treat OA patients without robust supporting evidence or comprehensive evaluation.
This review purposes to summarize clinical evidence regarding SVF as a therapeutic for OA and to introduce the author's perspective. Eleven studies were found suitable for this review; out of these, seven were randomized clinical trials and four were cohort studies.
A review of controlled studies suggests that SVF may offer better symptomatic relief than placebo or hyaluronic acid in the long term, and the effect of SVF is comparable to that of bone marrow aspirate concentrates.
Prospective studies with improved control over the cell isolation method, dosage, and patient selection are necessary to provide convincing evidence of the benefits of SVF in treating OA.
近年来，基于细胞疗法的再生医学已成为骨关节炎（OA）治疗的一种可能方法。基质血管成分（SVF）是一种通过机械或酶分离从抽脂物中获得的细胞混合物。SVF已在多个国家应用于治疗OA患者，但缺乏有力的支持证据和全面评估。
本综述旨在总结有关SVF治疗OA的临床证据，并介绍作者的观点。发现有11项研究适合本综述；其中，7项为随机临床试验，4项为队列研究。
对照研究综述表明，从长期来看，SVF可能比安慰剂或透明质酸能提供更好的症状缓解，且SVF的效果与骨髓抽吸浓缩物相当。
有必要进行前瞻性研究，更好地控制细胞分离方法、剂量和患者选择，以提供令人信服的证据证明SVF治疗OA的益处。
